LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT

Yuranos™ Abdominal Aortic Stent Graft System obtained registration approval from the China NMPA

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 23 November 2021, the Group's self-developed Yuranos™ Abdominal Aortic Stent Graft System ("**Yuranos™**" or the "**Device**") obtained registration approval from the China National Medical Products Administration ("**NMPA**").

Yuranos™ is used for the treatment of subrenal abdominal aortic aneurysms. Compared with products in the same category, it is suitable for more complex tumor morphology, can meet more complicated clinical anatomy and has a wider range of indications: the proximal end of the abdominal aortic aneurysm has a minimum tumor neck length of 10mm and a maximum subrenal angle of 75°. The device has a split design, which includes an Abdominal Aortic Bifurcation Stent Graft System and an Iliac Artery Extension Stent Graft System. Each system includes a stent graft and a delivery system. The stent graft is composed of a nickel-titanium skeleton and a PET film. Each stent graft is loaded in its own delivery system, and the stent graft is delivered and released to a predetermined position during the operation. The device also has a unique design, which can effectively improve the effect of intraoperative and long-term treatment, and reduce the risk of complications: i) the barb at the proximal bare end of the cover of the main body and the closed-loop mini

support wave design increase the anchoring, adhesiveness and flexibility of the Abdominal Aortic Bifurcation Stent Graft, effectively preventing displacement and type I endoleak; ii) the barbed design of the Iliac Artery Extension Stent Graft enhances the connection force between components, and effectively prevent type III endoleak caused by the component falling off; iii) the post-release function of the delivery system is combined with the anchoring area design of the stent graft component to achieve accurate positioning and control and improve the availability of the device and the success rate of immediate surgery.

The group will continue with independent innovation, and work with industry experts to advance the development and marketing of innovative medical device products to benefit patients.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 24 November 2021

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.